

Xolair®

M R F

Novartis

Injektionsvätska, lösning i förfylld spruta 75 mg

(Utseende: Klar till lätt opalskimrande, ofärgad till svagt brun-gul lösning.)

Medel vid obstruktiva lungsjukdomar, övriga systemiska medel för obstruktiva lungsjukdomar

Aktiv substans:

Omalizumab

ATC-kod:

R03DX05

Läkemedel från Novartis omfattas av Läkemedelsförsäkringen.

Miljöpåverkan

Omalizumab

Miljörisk: Användning av aminosyror, proteiner och peptider bedöms inte medföra någon miljöpåverkan.

Detaljerad miljöinformation

The use of amino acids/peptides/proteins has been considered to result in an insignificant environmental impact.

According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.

It is expected that any administered monoclonal antibody is completely metabolized and absorbed in the body. Any medicinal product that reaches water streams *via* spills during an application or after disposal of the unused drug, is expected to be very rapidly degraded and mineralized to CO₂ by microbial activity.

References

- EMEA/CHMP/SWP/4447/00 corr 2. Guideline on the environmental risk assessment of medicinal products for human use. London, 01 June 2006.
- Environmental classification of pharmaceuticals at (www.fass.se)
- Guidance for pharmaceutical companies 2012